Kornimate/medical-research-clean huggingface dataset:
blood nitrate/nitrite concentrations following acute ingestion of resync in men and women

Conditions: Healthy

Summary: this study evaluates acute ingestion of the dietary supplement resync on blood nitrate/nitrite concentrations in a sample of men and women. this will be a crossover trial in which participants take all 4 conditions: 1) 7.5g resync, 2) 15g resync, 3) 20g resync+collagen, 4) placebo.

the product known as resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid. manufacturers of resync recommend users take this product 60-90 minutes before an athletic event or 30-90 minutes after exercise. resync bases these claims on prior studies investigating the individual ingredients' abilities to increase blood nitrate/nitrite levels; however, there are no clinical trials on the finished product itself. the purpose of this pilot study is to determine the impact of acute, single ingestion of resync products on blood nitrate/nitrite concentration in a sample of men and women. this will be a crossover trial in which participants take all 4 conditions: 1) 7.5g resync, 2) 15g resync, 3) 20g resync+collagen, 4) placebo.

Eligibility criteria:
inclusion criteria: * bmi 18 - 29.9 kg/m2 * non-smoker * non-vegan * not using nitrate-based dietary supplements exclusion criteria: * diagnosed history of diabetes * diagnosed history of cardiovascular disease * diagnosed history of neurological disease * pregnant females

Keywords: resync nitrate nitrite healthy
clinical and radiographic outcomes of class ii furcation defects management using propolis: a case series

Conditions: Furcation Defects

Summary: furcation involvement represents a challenge for treatment to many periodontists due to many factors including access, morphology, and variations of anatomical features of the furcation area. furcation involvement treatment includes non-surgical periodontal therapy, resective surgery and regenerative surgery, regenerative therapy utilizing different graft materials and membranes is of high cost and research for new materials that can be cost-effective and available for all patients is continuing, propolis have been shown to be cost-effective therapy for bone and wound healing.

propolis is a natural resinous product of the bee workers collected from trees to use it to stick their hives and form a coat to protect their hives from all sources of bacteria and invasions. propolis is composed of more than 300 compounds, the most important of them are flavonoids like cape (caffeic acid phenyl ester). propolis have shown anti-inflammatory, anti-oxidant, anti-bacterial, anti-fungal, anti-viral and more importantly regenerative effect and bone formation capabilities.

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. lower molars with class ii furcation defects. 2. full mouth plaque score (fmps )\<20% at baseline. 3. full mouth bleeding score (fmbs )\<10% at baseline. 4. systemically healthy. 5. cooperative patients. exclusion criteria: * exclusion criteria: 1. smokers. 2. pregnancy and lactation. 3. stage 4 grade c periodontitis.
clinical evaluation of four aesthetic restorations in non-carious cervical lesions

Conditions: Noncarious Cervical Lesions

Summary: to compare the clinical performance of high-viscosity glass ionomer, flowable composite, bulkfill composite and nanohybrid composite restorations in non-carious cervical lesions (nccls).

one hundred fourty nccls were randomised into four groups according to a split-mouth design. clinical evaluations will be performed after 1 week, 3 months, 6 months, using fdi (world dental federation) criteria.

Eligibility criteria:
inclusion criteria: * had at least four non-carious symmetrical cervical lesions, * had permanent dentition and were older than 20 years old, * had cervical margins in dentin exclusion criteria: * periodontal disease * pregnant or breastfeeding * being under orthodontic therapy

Keywords: high-viscosity glass ionomer bulkfill composite flowable composite nanohybrid composite cervical lesion
a trial of an integrated clinic-community intervention in children and adolescents with obesity (hearts and parks)

Conditions: Childhood Obesity; Pediatric Obesity; Quality of Life; Cardiovascular Risk Factor

Summary: the investigators propose a randomized controlled effectiveness trial to evaluate the integrated clinic-community model of child obesity treatment as compared with routine primary care.

the purpose of this study is to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) affect children's health. the investigators will be looking at changes in child bmi, physical activity, nutrition, and overall health. the investigators also hope to better understand biological differences in metabolism and the microbiome (the bacteria that grows normally on and in the body) in children with high bmi who are making lifestyle changes.

Eligibility criteria:
inclusion criteria: * child age 5-18 years * child body mass index ≥ 95th %ile * parent can speak and read in english or spanish * parent ownership of a device that is able to receive and send text messages exclusion criteria: * live farther than a 20-mile radius from the healthy and fit program site * endogenous or genetic cause of obesity * taking a medication that causes weight gain * participation in a pediatric weight management program within 12 months * parent or child significant health problem that would limit participation * enrollment is above the max weekly enrollment of 60 participants/week) * reported or planned pregnancy opt-out criteria • primary care physician opts patient out of study for reasons including: severe obesity, urgent co-morbidities, parental unwillingness to be contacted by a research assistant, or at physician clinical judgment.
clinical study to evaluate the possible efficacy of dapagliflozin and atorvastatin in patients with major depressive disorders

Conditions: Depressive Disorder

Summary: major depressive disorder (mdd) is a significant cause of disability that affects approximately 16% of the world's population and is associated with chronic inflammation. although the mechanisms of mdd have not yet been clearly elucidated, nlrp3 inflammasomes have been implicated in the pathogenesis of depression.nlrp3 inflammasome is an intracellular multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a procaspase-1 precursor. it is well known that a variety of danger signals, such as pathogen-associated molecular patterns and danger-associated molecular patterns can activate nlrp3 inflammasome


Eligibility criteria:
inclusion criteria: - age ≥ 18 years both males and females will be included negative pregnancy test and effective contraception. depressed patients for at least 2 months with a hamilton rating score of more than 18. exclusion criteria: * patients with bipolar i or bipolar ii disorder * patients with personality disorders * patients with eating disorders * patients with substance dependence or abuse * patients with concurrent active medical conditions * patients with a history of seizures * patients with a history of receiving electroconvulsive therapy (ect) * patients with inflammatory disorders * patients with allergies or contraindications to the used medications * patients with finally pregnant or lactating females * diabetic or hyperlipidaemic patients
recover l-prp in lateral epicondylitis (regp-11-00)

Conditions: Lateral Epicondylitis

Summary: the objective of the study is to further characterize the performance of l-prp prepared using the biomet recover kit in the treatment of chronic le. the study will explore the potential impact of patient demographics and baseline characteristics on treatment outcome. furthermore it will track and document treatment effects, time course, and untoward effects following treatment of chronic le with l-prp from the recover device. in addition, the utilization of healthcare resources and associated costs will be investigated in treated patients.

clinical trials have been conducted to determine the efficacy and safety of leukocyte- and platelet-rich plasma (l-prp) prepared with biomet recover l-prp mini platelet separation kit for the treatment of tendinosis in a controlled setting. this study will allow for the capture and evaluation of real-world clinical data on a chronic le patient population. the advantage of a post-market data collection is that it provides a way to examine clinical and patient reported outcomes along with the associated costs of chronic le treatment in a diverse, clinically-relevant population. although several registries exist which capture the outcomes following tendon/ligament reconstruction surgery, there are no known registries that capture outcomes following non-surgical treatment of chronic le with recover l-prp. this study will fill that gap by allowing for an efficient data collection platform in a larger heterogeneous population of patients suffering from chronic le and will document and more closely examine the treatment effects of recover l-prp.

Eligibility criteria:
inclusion criteria: 1. signed an independent ethics committee (iec)-approved informed consent form (icf). 2. male or female of ≥ 18 years of age 3. confirmed diagnosis of unilateral chronic le 4. duration of chronic le symptoms ≥ 3 months 5. failed at least one previous le treatment (e.g. wait and see, physiotherapy, analgesics, nsaids, anti-inflammatory steroid injection and bracing, etc.). exclusion criteria: 6. no active systemic inflammatory condition (e.g., rheumatoid arthritis) 7. no active leukemia or metastatic malignant cells 8. no current chemotherapy treatments 9. no pregnancy 10. no lactation 11. no infected tendons, skin infection or skin disease in the area of the injection site. 12. participating in another drug or device study.

Keywords: chronic lateral epicondylitis leukocyte- and platelet-rich plasma recover-l-prp
study of tlk286 (telcyta) vs. gefitinib in locally advanced or metastatic non-small cell lung cancer

Conditions: Non Small Cell Lung Carcinoma

Summary: the purpose of this study is to determine if tlk286(telcyta) is more effective than gefitinib (iressa) in the treatment of non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of non-small cell lung cancer * non-small cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation * failed two prior chemotherapy regimens which must have included platinum * measurable disease exclusion criteria: * treatment with more than two prior chemotherapy regimens * history of bone marrow transplantation or stem cell support * pregnant or lactating women * known history of prior gefitinib therapy * known history of prior tlk286 therapy
effects of virtual reality versus motor imagery in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy is a neurodevelopmental disorder caused by brain injury that appears in infancy, children have mostly issues of gross motor functions, and activities of daily living. virtual reality is an innovative technique for the improvement of balance and motor function in most of the neurological conditions. motor imagery is an ability to engage in the mental representation of a task consciously without generating a voluntary movement. the aim of this study is to determine the comparative effects of virtual reality and motor imagery on balance, gross motor function and activities of daily living in children with cerebral palsy.

this randomized controlled trial will be conducted at rising sun institute. the sample size calculated for this trial will be 75. the participants will be randomly allocated using online randomization tool into three groups; group a will receive routine physical therapy (pt) for 30 minutes with additional selected exercises for 15 minutes, group b will receive vr training for 15 minutes with routine pt for 30 minutes, and group c will receive mi for 15 minutes and routine pt for 30 minutes. each participant will receive treatment for three days on alternative days per week for 12 weeks. gross motor function scale (gmfcs) will be used for balance, bruininks-oseretsky test of motor function proficiency-2 (bot-2 ) for motor function, and weefim scale for adls at baseline, 8th week, 12th week, and at 16th week after discontinuation of treatment.

Eligibility criteria:
inclusion criteria: children of 7-12 years of both genders, children with mini mental scale score \>24. children with gross motor function classification system (gmfcs) level i and ii and able to follow and accept verbal instruction. exclusion criteria: history of any visual and hearing impairments, virtual game phobia. history of nerve, muscle, bone and joint diseases that seriously affect the movement function of the limbs and children with history of severe cardiopulmonary disease, history of epilepsy, history of fixed deformity of lower limb. history of orthopaedic surgery and botulinum toxin injection.

Keywords: cerebral palsy motor control activities of daily living randomized controlled trial
riociguat-discontinue effects on right heart in cteph (red-heart)

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Summary: riociguat and balloon pulmonary angioplasty (bpa) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (cteph) with comparable evidence levels. however, the optimal combined treatment strategy remains unclear. specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with bpa. additionally, the long-term effects of riociguat discontinuation on right ventricular (rv) structure and function remain poorly characterized, particularly due to the lack of comprehensive noninvasive evaluations integrating cardiac magnetic resonance (cmr) and echocardiography. this prospective study aims to determine the hemodynamic impact of riociguat discontinuation in inoperable cteph patients who have achieved bpa treatment endpoints using right heart catheterization (rhc). evaluate rv remodeling and functional changes after riociguat cessation through multimodal noninvasive imaging (cmr, echocardiography). assess safety outcomes and identify potential rebound pulmonary hypertension or decompensated rv dysfunction associated with riociguat withdrawal.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * cteph was diagnosed and one of the following three factors was met: pulmonary endarterectomy was technically impossible; pulmonary endarterectomy is technically feasible, but the risk-benefit ratio is poor; residual/recurrent pulmonary hypertension after pulmonary endarterectomy * subjects had been treated with bpa and had received a stable dose of riociguat for ≥12 weeks * mpap \< 30mmhg * male subjects and female subjects of reproductive age are required to use effective contraception for at least 28 days after signing the informed consent form. male subjects are not allowed to donate sperm and female subjects are not allowed to breastfeed. * subjects voluntarily sign written informed consent exclusion criteria: * severe hepatic and renal insufficiency (child-pugh grade c/creatinine clearance \< 30ml/min·1.73m²) * the presence of severe infectious disease or severe bleeding tendency * combined with pulmonary hypertension of other types than cteph * other pulmonary hypertension targeting drugs are being used * the expected survival time with cancer or other diseases is less than 6 months * pregnancy, lactation * subjects are currently participating in an interventional clinical trial * in the investigator's judgment, a subject's medical abnormality, physical condition, or medical history may affect his or her ability to participate in or complete the study

Keywords: chronic thromboembolic pulmonary hypertension riociguat right heart function
effectiveness of gut microbiota-targeted diatery intervention among older people living with hiv

Conditions: Hiv; Atherosclerosis; Diet, Healthy

Summary: the goal of this clinical trial is to conduct a dietary intervention targeting hiv specific gut microbiota alterations for primary atherosclerotic cardiovascular disease (ascvd) prevention and evaluate its effectiveness in preventing ascvd among older people living with hiv (plwh).

the investigators utilize a pragmatic randomized controlled trial design to evaluate the effectiveness of dietary intervention in real-world conditions, without strict control, thereby enhancing the generalizability and clinical applicability of our study findings. participants at shenzhen third people's hospital, exhibiting hiv with cvd risk will be enrolled. upon providing informed consent, participants will undergo dynamic randomization into intervention and control groups, aiming for a 1:1 ratio while preserving maximum unpredictability. the intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly healthy diet guidance for the same duration. meanwhile, the control group will continue routine follow-up and health education practices. the intervention will span three months, followed by a three-month follow-up period. data collection will occur at baseline, 3 months, and 6 months. primary outcomes will assess ascvd risk via the pooled cohort equation and evaluate gut microbiota diversity and composition. secondary outcomes will encompass biomarkers and predictors associated with atherosclerotic cardiovascular disease, as well as symptoms related to the condition.

Eligibility criteria:
inclusion criteria: 1. hiv-infected patients diagnosed according to the diagnostic criteria of china aids diagnosis and treatment guidelines; 2. aged 40 years and above; 3. at risk of cvd: having any two of those risk factors: dyslipidemia, dm or elevated blood glucose, smoking, hypertention or elevated blood pressure, metabolic syndrome,overweight/obesity; or pce score\>5%, 4. those with a predicted survival time of \>1 year; 5. no plans to leave the depth in the next 3 months; 6. voluntary participation in this study and signing the informed consent exclusion criteria: 1. those with a previous history of cvd; 2. those with hiv-related neurocognitive impairment, alzheimer's disease or dementia, and a variety of serious opportunistic infections; 3. currently suffering from malignant tumors, gastrointestinal diseases; people with an aversion to eating; 4. allergic to nuts and fish; 5. people who take medicinal calcium \>1000 mg per day or omega-3 supplements; 6. plan to become pregnant within 6 months; 7. are participating in other hiv-related or dietary intervention-related scientific research programs.
management of depression and social isolation in older adults with dementia with home-based telehealth delivered behavioral activation + caregiver facilitation.

Conditions: Depression

Summary: the purpose of this study is to evaluate the feasibility of using behavioral activation therapy with caregiver support delivered via telemedicine to older adults with depression and probable mild dementia.


Eligibility criteria:
inclusion criteria: participant eligibility criteria: * able to speak and understand english; * a diagnosis of mild dementia, as determined by a clinical dementia rating interview sum of boxes (cdr-sb) score in the mild range as defined by a score of 4.5 - 9.0; * and able to provide informed consent. caregiver eligibility criteria. * beck depression inventory (bdi) score below clinical cutoff for depression and able to provide informed consent. exclusion criteria: participant exclusion criteria: * presence of suicidal ideation with clear intent, * concurrent enrollment in another clinical trial for depression, * substance use disorder. caregiver exclusion criteria: * active psychosis or significant dementia at screening; * presence of suicidal ideation with clear intent.

Keywords: social support dementia caregivers
high carbohydrate vs. high fat diets in the treatment of obesity (jbr 0512)

Conditions: Obesity

Summary: the purpose of this study is to compare the ability of low calorie high carbohydrate and low calorie high fat/protein diets to decrease abdominal fat in overweight and obese subjects. the investigators will also test the effects of these diets on secondary outcomes including body composition, fluid and electrolyte balance, lipids and lipoproteins, blood pressure, arterial compliance, glucose and insulin metabolism, bone turnover, and measures of satiety.

participation in this study requires 2 screening visits to the outpatient clinic, and if participants qualify, 10 inpatient study weeks. subjects will be admitted to the rockefeller university hospital for the 10 week in-patient phase of the study. the first 2 weeks consist of a weight stabilization period, during which subjects will be required to consume an average american diet. this is followed by the 6 week weight loss period where subjects will be randomized to either a low calorie high carbohydrate or a low calorie high fat/protein diet. on both diets there will be a 50% calorie deficit compared to the weight stabilization period. this will be followed by a 2 week weight maintenance period during which calories will be added to the diet to maintain the new weight. appropriate adjustments will be made to keep the subject's weight stable. during the entire inpatient study, subjects will consume one multivitamin per day (centrum, always complete, from a to zinc) and one iron supplement per day. in addition, unlimited access to zero calorie liquids (water/diet soda) will be available and will be encouraged to maintain one's usual activity level. females of reproductive age, need to make sure that they do not become pregnant during the inpatient study. urine will be tested for pregnancy once during the stabilization and weight maintenance phases of the study.

Eligibility criteria:
inclusion criteria: * man or a woman with a body mass index (bmi) of 30 to 34.9 * man with a bmi of 25 to 29.9 with a waist circumference \> 102cm (40in) * woman with a bmi of 25 to 29.9 with a waist circumference \> 88cm (35in) exclusion criteria: * high blood pressure * high cholesterol * diabetes * hiv positive * syphilis * hepatitis b/c positive

Keywords: overweight obese diet
a clinical study of grc 8200 in type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the study is aimed at evaluating efficacy and safety of grc 8200 in type 2 diabetes mellitus patients. the study involves six weeks of wash out period and two weeks run in period for patients currently on mono-therapy and a two week run in period only for drug naïve patients. this is a placebo controlled study. one of the five treatment arms is placebo. the duration of treatment is 12 weeks.


Eligibility criteria:
inclusion criteria: * male or female patients ≥30 years of age * at screening, females of non-childbearing potential or females of childbearing potential with adequate contraception * has an established clinical diagnosis of type 2 diabetes mellitus for at least 3 months prior to the screening period * is being treated for diabetes either with diet and exercise alone, or on monotherapy with any of the antidiabetic drugs * has an hba1c value at screening between 6.5% and 10% exclusion criteria: * has type 1 diabetes * is a female who is lactating or is pregnant * has a history of acute metabolic diabetic complications * has clinically significant disease other than type 2 diabetes mellitus

Keywords: type 2 diabetes mellitus grc 8200